Clinical trials: Respiratory Allergy
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
This study is a prospective observational cohort study with 3-month follow-up among a cohort of intranasal steroid (INS) -experienced patients newly starting fluticasone furorate nasal spray (FFNS).
- Trial name
- NCT01337323
- Testing
- Fluticasone furoate nasal spray
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Sarcoidosis
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients).
- Trial name
- NCT00955279
- Testing
- Golimumab, Ustekinumab
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 173 people
- Sponsor
- Centocor, Inc.
Allergic Rhinitis
Grazax Asthma Prevention
Investigation of the effect of Grazax (grass tablet) on asthma prevention in children with grass pollen allergy
- Trial name
- GAP (NCT01061203)
- Testing
- Grazax
- Where
- Finland
- Volunteers
- 812 people
- Sponsor
- ALK-Abelló A/S
Asthma, Allergy
Efficacy of Air Cleaners in Asthmatics Allergic to Cat in ALYATEC Environmental Exposure Chamber
The aim of this study is to determine the efficacy of Rowenta® "Intense Pure Air XL" air cleaner on the early and late bronchial response, in cat-allergic asthmatic patients during an allergen exposure in ALYATEC environmental…
- Trial name
- NCT03928561
- Testing
- Active intense Pure Air XL air cleaner
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Alyatec
Asthma
Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594
AZD7594 is in clinical development for the treatment of asthma. This is a single centre, open-label, single period study in 6 healthy subjects, to determine the mass balance recovery and generate samples to enable metabolite…
- Trial name
- NCT04002427
- Testing
- Intravenous Infusion, Inhaled dose
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in comparison to a Placebo-HFA control MDI and the…
- Trial name
- NCT01357642
- Testing
- Epinephrine inhalation aerosol
- Where
- 33 sites in United States
- Volunteers
- 373 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting
TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G…
- Trial name
- TRIMAXIMIZE (NCT06100042)
- Testing
- BDP/FF/G
- Where
- Italy
- Volunteers
- 233 people
- Sponsor
- Chiesi Italia
Allergic Rhinitis
Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis
The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate …
- Trial name
- NCT01055756
- Testing
- Loratadine + Pseudoephedrine sulfate
- Where
- Brazil
- Sponsor
- Azidus Brasil
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197234
- Testing
- Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)
This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days…
- Trial name
- NCT00794599
- Testing
- Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec)
- Volunteers
- 118 people
- Sponsor
- Organon and Co
Asthma
Relovair PD PK in Chinese Healthy Subjects
In this study, fluticasone furoate (FF) and vilanterol (VI) in different dose combinations (50/25mcg, 100/25mcg and 200/25mcg) will be administered from a single dry powder device to evaluate the PD, PK, safety and tolerability…
- Trial name
- NCT01711463
- Testing
- Fluticasone Furoate/Vilanterol
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Conjunctivitis, Seasonal Allergies
A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
This is a randomized, parallel, single center, double masked, vehicle controlled study. The purpose of this study is to determine the activity and safety of NS2 in patients with grass, tree or ragweed-pollen induced seasonal…
- Trial name
- NCT02578914
- Testing
- NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Asthma
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066/ABBV-066 (risankizumab) as compared to placebo over a 24-week treatment period in severe asthma patients.
- Trial name
- NCT02443298
- Testing
- risankizumab
- Where
- 65 sites in United States, Belgium and 8 more
- Volunteers
- 214 people
- Sponsor
- AbbVie
Asthma
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
This study aims to determine the prevalence of Asthma, Difficult-to-Treat and Severe Asthma in Portugal, and characterize patients to better understand their disease characteristics, treatment profile and health care resource use…
- Trial name
- Epi-Asthma (NCT05169619)
- Where
- 37 sites in Portugal
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Prevalence and Reversibility of Lung Hyperinflation in Asthma
The aim of this observational study is to evaluate the pulmonary hyperinflation and its immediate reversibility to a short acting beta2 agonist test in uncontrolled persistent asthmatic patients with dyspnea.
- Trial name
- Dist'air2 (NCT01573364)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
The purpose of this study is to evaluate the safety of two doses (6 Development Units [DU] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic…
- Trial name
- NCT01678807
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 195 people
- Sponsor
- ALK-Abelló A/S
Asthma
A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)
This was a 2-part study in participants with allergen-induced asthma. It included a procedural pilot component (Part 1). Part 1 tested the key procedures and timing of Part 2; no study drug was administered during Part 1.
- Trial name
- NCT01343407
- Testing
- MK-1029 10 mg, MK-1029 100 mg
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function…
- Trial name
- ATLAS (NCT05097287)
- Testing
- Dupilumab
- Where
- 249 sites in United States, Belgium and 21 more
- Volunteers
- 1,339 people
- Sponsor
- Sanofi
Allergic Rhinitis
Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy…
- Trial name
- NCT05170763
- Testing
- PA9159 nasal spray solution, 10 μg one day treatment, PA9159 nasal spray solution, 20 μg one day treatment, PA9159 nasal spray solution, 40 μg one day treatment
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anhui Palo Alto Pharmaceuticals, Inc.
Asthma
Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils
A multi-center, randomized, open-label, parallel-group, repeat dose study in asthma patients with elevated eosinophils. Eligible subjects will receive 3 doses (28 days apart) of mepolizumab given intravenous (IV) or…
- Trial name
- NCT01366521
- Testing
- Mepolizumab
- Where
- 11 sites in United States, Estonia and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.